Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The company sees the business reaching $100mn
Monetary awards worth Rs 1.20 crore were presented amongst the winners for their remarkable contributions
Subscribe To Our Newsletter & Stay Updated